Teva announced the launch of Daunorubicin HCl Injection in NovaPlus label, the generic version of Bedford LaboratoriesCerubidine Injection.

Daunorubicin HCl is an anthracycline indicated in combination with other chemotherapy for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. Daunorubicin HCl forms complexes with DNA by intercalation between base pairs, and inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.

Daunorubicin HCl Injection is available as a 5mg/mL concentration in 4mL glass vials.

For more information call (888) TEVA-USA or visit